Dear Editor,
The ability of a cell to avoid apoptosis in response to genotoxic stress is of central importance in its progression to a malignant phenotype, and to the acquisition of drug resistance in cancer. 1 In the course of studies of the relationship between resistance to chemotherapeutic agents and expression of apoptosis-modulating genes, we used RT ± PCR to examine bax mRNA in the non-small cell lung cancer cell line NCI-H460V. PCR primers based upon the published cDNA sequence for bax a 2 were designed to amplify bax sequences incorporating exons 1 to 6 ( Figure 1A ). Predictably a major band of approximately 580 bp consistent with bax a was observed, accompanied by a smaller product of approximately 430 bp, corresponding to the recently described bax d.
3 However, we also detected PCR products of approximately 620 bp and 380 bp, which did not correspond to previously identified bax splice variants. The sequences of the two unidentified PCR products were consistent with novel splicing arrangements of the bax gene. The smaller of the two products appeared to be missing exons 2 and 3 but was otherwise identical to bax a. To provide continuity of nomenclature, we have named this variant bax e. The larger (*620 bp) PCR product contained all six exons of the bax gene; however, the cDNA sequence indicated the presence of a 49 bp insert between exons 5 and 6 consistent with a fragment of intron 5 containing an unrecognised sequence. Further detailed PCR analysis suggested that this insert is derived from the 3' end of intron 5. We named this new variant bax f. Kyte-Doolittle analysis confirmed that Bax f protein contains no hydrophobic regions that might correspond to a transmembrane domain.
In vitro transcription and translation was used to determine whether these novel sequences would generate proteins ( Figure 1B ). Full-length cDNAs corresponding to bax a, d, e and f were generated by RT ± PCR and cloned into the expression vector pCR3.1. The bax a construct gave rise to a radiolabelled product with a molecular weight of 21 kDa upon gel electrophoresis as expected, while bax f gave a single predicted product of 24 kDa. No protein band was seen with the bax e construct, which was predicted to produce a 1 kDa polypeptide. Western blotting of lysates prepared from the NCI-460V cell line with antiBax antibody N-20 (Santa Cruz Biotechnology, CA, USA) revealed protein bands of approximately 21 and 24 kDa (data not shown). The 24 kDa protein may correspond to Bax f, but could also represent Bax b, which has the same predicted mass. 2 Having demonstrated that bax f could potentially give rise to a 24 kDa protein lacking a transmembrane domain, we carried out experiments to determine whether this protein has biological function. For this purpose, Bax f protein was over-expressed in Jurkat cells using the pTRE Tet-off transient expression system (Clontech) Figure 1C) . 4 By 8 h post-transfection with bax a, approximately 12% of the Jurkat cells were apoptotic, 4% more than seen after transfection with empty vector. The apoptotic population increased to a plateau at about 14% (significantly different from empty vector; P50.05) by 20 h, which was maintained until the last time-point at 44 h. Following transfection with bax f, apoptosis was induced to levels comparable with bax a by 44 h, although the full effect was not apparent until 28 h, at which time-point the level of apoptosis in bax ftransfected cells was not significantly different from bax atransfected cells.
The significance of bax mRNA splice variants is unclear. A comprehensive immunohistochemical analysis 5 has suggested that Bax protein is present in a wide range of normal mouse tissues, in particular those characterised by a high apoptotic death rate. Furthermore, immunoblotting of these tissues shows that 21 kDa Bax a is the predominant protein product. Oltvai et al 2 also demonstrated a 24 kDa species on immunoblotting consistent with Bax b; however this translated product was not sequenced. As yet no convincing evidence exists for the translation in vivo of bax d or g.
One of the new isoforms we describe here appears to be identical to that described very recently by Zhou et al 6 and termed bax o, which contains a 49 base insert from intron 5, between exons 5 and 6. Using ribonuclease protection assays, Zhou et al 6 demonstrated that bax o is widely distributed in human heart, brain and liver. By RT ± PCR, we have detected mRNAs for bax f, as well as for e and d, in a wide range of cultured cells, both primary and established lines.
Our data suggest that transient bax f over-expression induces apoptosis in Jurkat cells at levels comparable to bax a, although the effect appears to be slightly delayed. Zhou et al 6 using a different system to functionally characterise bax o, obtained broadly similar results. Interestingly their data for bax o suggest that overexpression protects stably-transfected L929 cells from TNF-induced apoptosis; however transient over-expression of bax o increases basal levels of cell death in monkey E5 cells to levels greater than those seen with bax a. 6 There may be problems inherent in the use of stable transfectants that could explain what appears to be an anomalous result. Stable transfectants of Jurkat cells over-expressing Bcl-2 contain markedly higher steady-state levels of endogenous Bax. 7 The inference of these data is that the clones that are selected may contain other proteins that affect their response to apoptosis, and inadvertently a non-representative clone has been selected for.
In summary, we have demonstrated the occurrence of two novel splice variants of the bax gene, one of which lacks a transmembrane domain but retains pro-apoptotic function. While the physiological significance of this finding is unclear, a parallel situation is to be found in the existence of splice variants of the Bcl-2 gene. One isoform of Bcl-2 encodes a protein that lacks a transmembrane domain. 8 In two studies truncated forms of Bcl-2 retain antiapoptotic function, 2,9 while in another it is lost.
